STOCK TITAN

Athira Pharma, Inc. (ATHA) EPS by Year

ATHA

Athira Pharma, Inc. lost $24.70 per diluted share in fiscal year 2025. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Athira Pharma, Inc. has filed alongside them.

FY2025 annual
EPS (Diluted) -$24.70
Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

ATHA EPS (Diluted) by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY23FY22FY21FY20FY19
EPS (Diluted)-$24.70-$25.19-$3.09-22.1%-$2.53-69.8%-$1.49N/AN/A

ATHA EPS (Diluted) by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'23Q3'23Q2'23
EPS (Diluted)-$1.73N/A-$1.68-$0.18+74.3%-$2.34N/A-$7.46-$0.70+10.3%-$0.69+5.5%N/A-$0.87-64.2%-$0.78-20.0%

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More Athira Pharma, Inc. financials

Frequently Asked Questions

What was Athira Pharma, Inc.'s diluted earnings per share in fiscal year 2025?

Athira Pharma, Inc. lost $24.70 per diluted share in fiscal year 2025.

What was Athira Pharma, Inc.'s diluted earnings per share in the most recent quarter?

Athira Pharma, Inc. (ATHA) reported -$1.73 in diluted earnings per share in Q1 2026.

What does diluted earnings per share mean on a financial statement?

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Athira Pharma, Inc. (ATHA) reported on that line in every period on record.